Literature DB >> 30678533

Mortality and Prognostic Prediction in Very Elderly Patients With Severe Pneumonia.

Moon Seong Baek1, Sojung Park1, Jeong-Hee Choi1, Cheol-Hong Kim1, In Gyu Hyun1.   

Abstract

INTRODUCTION: Although prognostic prediction scores for pneumonia such as CURB-65 score or pneumonia severity index (PSI) are widely used, there were a few studies in very elderly patients. The aim of the study was to validate prognostic prediction scores for severe pneumonia and investigate risk factors associated with in-hospital mortality of severe pneumonia in very elderly patients.
METHODS: During the 6-year study period (from October 2012 to May 2018), 160 patients aged 80 or older admitted to medical intensive unit were analyzed retrospectively. Pneumonia severity was evaluated using CURB-65 score, PSI, Sequential Organ Failure Assessment (SOFA) scores, A-DROP, I-ROAD, UBMo index, SOAR score, and lactate. The outcome was in-hospital mortality.
RESULTS: The median age was 85 years (interquartile range: 82-88). Nursing home residents accounted for 71 (44.4%) and in-hospital mortality was 40 (25.0%). Logistic regression showed that chronic lung, mechanical ventilation, hemodialysis, and albumin were associated with in-hospital mortality of pneumonia. Using the receiver operating characteristics curve for predicting mortality, the area under the curve in pneumonia was 0.65 for the SOFA score, 0.61 for the CURB-65 score, 0.52 for the PSI, 0.58 for the A-DROP, 0.52 for the I-ROAD, 0.54 for UBMo index, 0.59 for SOAR score, and 0.65 for lactate.
CONCLUSION: The performances of the CURB-65 and PSI are not excellent in very elderly patients with pneumonia. Further studies are needed to improve the performance of prognostic prediction scores in elderly patients.

Entities:  

Keywords:  elderly; mortality; pneumonia; severity index

Mesh:

Year:  2019        PMID: 30678533     DOI: 10.1177/0885066619826045

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  6 in total

1.  Ulinastatin plus biapenem for severe pneumonia in the elderly and its influence on pulmonary function and inflammatory cytokines.

Authors:  Rui Zhang; Jitao Ma; Pengxiao Zheng; Ruirui Zheng; Xu Meng; Yinjia Wang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Development and validation of a new scoring system for prognostic prediction of community-acquired pneumonia in older adults.

Authors:  Masahiro Shirata; Isao Ito; Tadashi Ishida; Hiromasa Tachibana; Naoya Tanabe; Satoshi Konishi; Issei Oi; Nobuyoshi Hamao; Kensuke Nishioka; Hisako Matsumoto; Yoshiro Yasutomo; Seizo Kadowaki; Hisashi Ohnishi; Hiromi Tomioka; Takashi Nishimura; Yoshinori Hasegawa; Atsushi Nakagawa; Toyohiro Hirai
Journal:  Sci Rep       Date:  2021-12-13       Impact factor: 4.379

3.  Efficacy of phentolamine combined with ambroxol aerosol inhalation in the treatment of pediatric severe pneumonia and its effect on serum IL-10 and CRP levels.

Authors:  Junxia Li; Haixia Wu; Jingyao Zhang
Journal:  Transl Pediatr       Date:  2022-01

4.  Development and Validation of a Nomogram for Predicting 28-Day Mortality on Admission in Elderly Patients with Severe Community-Acquired Pneumonia.

Authors:  Yansha Song; Xiaocen Wang; Ke Lang; Tingting Wei; Jinlong Luo; Yuanlin Song; Dong Yang
Journal:  J Inflamm Res       Date:  2022-07-21

5.  Sequential treatment of severe pneumonia with respiratory failure and its influence on respiratory mechanical parameters and hemodynamics.

Authors:  Bing-Yin Niu; Guan Wang; Bin Li; Gen-Shen Zhen; Yi-Bing Weng
Journal:  World J Clin Cases       Date:  2022-07-26       Impact factor: 1.534

6.  Clinical profile analysis and nomogram for predicting in-hospital mortality among elderly severe community-acquired pneumonia patients with comorbid cardiovascular disease: a retrospective cohort study.

Authors:  Linjing Gong; Dingxiu He; Dong Huang; Zhenru Wu; Yujun Shi; Zongan Liang
Journal:  BMC Pulm Med       Date:  2022-08-13       Impact factor: 3.320

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.